Evgen Pharma Share Discussion Threads

[l0ngterm] 04/5/2018 11:23

We Might have the interim readout beforehand then. It would definitely add more to the presentation.

[nico115] 04/5/2018 11:16

I'm fully loaded nowWas expecting 15p but 17p held and that's good news so bought a chunk at 18.3p avge

[timbo003] 04/5/2018 09:04

I see that the company are presenting on two consecutive days later this month

May 16th: ShareSoc
May 17th: Proactive one2one




Investors and prospective investors based in the SE /London should try to get along to one or the other, I shall attend both.

[bernymadoff] 03/5/2018 18:52

The company is well aware of the value of sfx-01 so it's hardly surprising that it is wasting no time getting the patent protection in place.

[pdt] 03/5/2018 16:27

One of the things I like about EVG is that they do have good patent protection on SFX-01 and it is applicable potentially to so many other diseases.

For example I have seen FIVE research articles published this year showing the benefit of Sulforaphane in respect of treating Alzheimer's. A huge market and potentially changing the lives of millions of people worldwide.

[papillon] 03/5/2018 15:55

Let me state this, bernymadoff. I have NO knowledge of EVG. They might be the exception and they might well make long term shareholders fortune. I think the odds are against it, but there have been successful AIM listed biopharmas.

I hope AMYT will be another exception. It definitely has an experienced BoD, with the likes of Harry Stratford having an excellent CV. Fingers crossed. Buying shares in any AIM listed biopharma is just a gamble (IMM lth's will attest to that!)

PS I'm invested in AMYT despite it's sad looking chart.

[l0ngterm] 03/5/2018 15:47

I agree with the fact these shares can be driven by sentiment, and folk do play on this. However utilising the past performance as a bench mark maybe a tad miss leading. Taking the science trial out of this and focusing on inflection points. then IIs investing in the IPO would of had a 3-5 year projection. Based upon that the timeline,the key inflection points on the horizon, then any historical data could feasible be ignored.Also applying a forward looking stance, interim analysis update due, full trial results due in 8 months, and the compassionate use program ongoing (the significance of the duration, and the positive data collected is significant). Then we you could foreseeable project that this is the bottom. Combine the above with the key fact the SAH trial is being designed for conditional market approval, which is also on the 9 month horizon, and the company were not shy in delaying the trial previously, to maximise the opportunity.Then a lot has changed.

[bernymadoff] 03/5/2018 15:43

Join the dots............

Read the 24 April RNS carefully.

Our CEO was speaking at the World Orphan Drug Conference in the USA in the "Pitch and Partner" section.

"The presentation, which is part of the Pitch & Partner track of the congress, will focus on SFX-01, the Company's lead product, in the treatment of subarachnoid haemorrhage ("SAH"). SFX-01 is currently in a Phase II clinical trial in SAH, which remains on track to report around the end of 2018.

The presentation will also refer to the ongoing Phase II trial of SFX-01 in metastatic breast cancer, which is on track to report an interim read-out in Q2 this year with the final read-out around the year end."

Then visit the link to the conference website and look at the kind of companies that attended.

hxxp://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm.

They are the biggest and most well-known pharmas in the world including the likes of Sanofi, Pfizer and many more.

Now why would our CEO, whose presentation focusses on the use of SFX-01 for subarachnoid haemorrhage, sidetrack to talk about the ongoing trial of SFX-01 in metastatic breast cancer if he had any doubt at all that the interim results were going to be bad.

Also, why would Hardman which is commissioned by the company to write research notes, say that they expect the interim results to meet expectations unless they were told as much by the company?

The other thing that should inspire confidence is that institutions have been adding to their holdings lately. While this in and of itself is not a failsafe measure institutions do get passed more information than PI's.

All the signs here are pointing in the direction of very positive times ahead for this company. we saw last week just how quickly the share price can move in the event of any real buying demand. If the interim readouts continue to show that SFX-01 is successful in the treatment of metastatic breast cancer you can bet your bottom dollar that every man and his dog will want to jump on board for the big ride up.

[nico115] 03/5/2018 15:12

Institutions loaded up at 37p so they were always going to avge at 12pIN IMM AN INSTIT approached the company to invest millions ..see want they are now?How many drug companies find a cure? 1 pct? I bet it's less !!Mtfb passed phase 3 and are lower than IPo!! Bernay u keep ramping away

[bernymadoff] 03/5/2018 15:04

Only idiots look at the rise and fall of a share price to determine whether they should invest and at what price.

It wasn't long ago that institutions were paying 37p on IPO to get exposure to the drugs EVG are testing. Since then many of them have continued to buy and they currently hold 55% or so of the whole company.

Institutional investment is one of the major ingredients I look for when deciding to invest anywhere. It gives you a level of confidence knowing that experts have evaluated the company to a degree that lay people could not achieve.

Big plus there.

Then there is the performance of the company. To date EVG have not put a foot wrong and all their drug trials have exceeded market expectations.

Yet the market has not assigned any value to the progress the company has made since IPO in October 2015. Like many other pre-revenue AIM companies with great potential it has been at the mercy of the spivs in the city who have manipulated the share price down so that they can screw the company in the knowledge that it is dependent on placings to see it through to commercialisation.

There is a wealth of information out there showing just how disconnected the share price is to the actual potential of EVG. For me that's where the opportunity lies. The greater the disconnect the greater the correction (in fact in these cases the correction often overshoots to the overvalued side).

The other big thing the company has going for it is that it is funded through to the end of the year by which point it may well have landed a licensing or JV deal if the results due this quarter and then again at the end of the year are any good. Certainly the CEO has been dropping hints to that effect in recent rns'.

You can choose to play the swings or you can hold for the big prize that the evidence suggests is now within grasp.

[papillon] 03/5/2018 14:57

"Although could miss out on news". News can blow up any share price prediction based on a historical chart and I know nothing of the EVG fundamentals, nico. I'm only going by the chart in the header. In fact I'd never heard of EVG until I noticed moneytree posting on it. He was trolling/stalking me after I criticised him on another bb. I presume moneytree is a trade.

[nico115] 03/5/2018 14:44

Totally agree papillon Although could miss out on news Bernay is v long from 25p cos he followed top info in here Wonder if he will cut at 15p?Wouldn't surprise me the amount he ramps

[papillon] 03/5/2018 14:34

Looking at the long term EVG chart in the header the share price spiked up in Feb 2017, but within months the share price was back where it stated from. Over succeeding months the share price drifted below where the spike strted from, until the share price spiked up again in November. The share price then rapidly drifted back down to where the spike started from and then drifted below that point until the latest spike up. You wouldn't bet (well I wouldn't!) against the EVG share price again falling back to where the spike started from and then drifting below that point. History has a habit of repeating inself. If it does repeat itself this time the EVG share price could well drop back to circa 13p and then drift below. Will it? No idea, but I wouldn't take the risk by buying EVG at the current price. Best of luck to those that do.

Again the long term chart in the header shows that since hitting circa 32p back in Aug 2016 the EVG share price has been in decline ever since, the decline punctuated by those 3 spikes up. Of course the EVG share price could have bottomed out recently at circa 13p, but I wouldn't bet on it, though I concede others might!

PS Unfortunately the rampers and pumpers & dumpers that love AIM listed minnows like EVG (because it's relatively easy and cheap to influence the share price movement) descend on shares like EVG to exaggerate the effect of any good news on the share price

[nico115] 03/5/2018 14:10

Rathean Can't see it but hope so so I can buy the company!!Berny U r a liar Get lost I told you we going down and we have Eat humble pie ..u ramped this at 25p..saddo

[bernymadoff] 03/5/2018 13:39

Derampers getting desperate now, plucking random figures out of the air.

If this gets to 12p it will be because the interim readouts are carp. However I just can't see that happening, what with our CEO pitching the drug to pharma industry players only as recently as last week and the Hardman note stating they expect them to meet expectations.

Personally I'd like it to get to 1p so I can fill my boots but barring a black swan event it's never going to happen so I refrain from posting my fantasies on this board.

[rathean] 03/5/2018 12:29

Still got my 12p buy trigger set, reckon it'll be there within 2-4 weeks.

[bernymadoff] 03/5/2018 11:42

You seem obsessed with top info.

Is it a man crush or just jealousy?

[nico115] 03/5/2018 11:11

Berny U R the trader Denying there was 100k on offer the other day Denying topinfo tipped this a few times Liars get found out ...try telling the truth next time Berny

[bernymadoff] 03/5/2018 10:53

Nico you strike me as a day trader constantly commenting on small movements and changing your tune according to your trading position.

These minor fluctuations don't concern me as having done my research I believe the so is hugely undervalued in relation to both peer valuations and future prospects.

The traders have this at the moment but with interims readouts due any day it is just a matter of time before we push on into the 20s.

These dips are just an opportunity to buy more.

[nico115] 03/5/2018 10:32

Agreed long termWhether we bottom here or 15p I suppose is irrelevant as we are in for long termI just knew in the 20s was so puffy with topinfo and his mates ramping so they could sell..they don't tip and then buy ..they buy then tip and then sell..do it to hundreds of stks and then rarely mention them again!!Poor berny taken in by it all

[l0ngterm] 03/5/2018 10:23

Similar to myself (long), got feeling that this maybe bottom. But it is all guess work over a few pennies just now.

[nico115] 03/5/2018 10:03

Not hoping as I'm long but think we will drift to there or there abouts Not bothered as in a few weeks should be a lot higher if results are positive

[l0ngterm] 03/5/2018 10:00

Are you still hoping for 15?